-
Darolutamide vs Capecitabine in AR-Positive TNBC: UCBG 3-06 START Trial Results
On March 2025, The Lancet Oncology published results from the UCBG 3-06 START phase 2 trial, comparing darolutamide and capecitabine in patients with triple-negative, androgen receptor-positive (AR+) advanced breast cancer.Although…
-
TILs Predict Long-Term Survival in HER2+ Breast Cancer: 10-Year ShortHER Trial Insights
A decade after the start of the ShortHER trial, new data published in JAMA Oncology sheds light on how tumor-infiltrating lymphocytes (TILs) can guide treatment decisions in early ERBB2-positive (HER2+)…
-
Neoadjuvant Nivolumab Boosts pCR in High-Risk ER+/HER2− Breast Cancer
In a landmark phase 3 trial published in Nature Medicine, Prof. Sherene Loi and colleagues investigated whether immunotherapy can shift the treatment paradigm in high-risk early ER+/HER2− breast cancer.The study…
-
Mok Talk | Master Tony Mok on Research, Leadership, and the Future of Lung Cancer in China
As lung cancer diagnosis and treatment enter an era of precision and personalization, Chinese researchers are playing an increasingly pivotal role on the international stage through innovation and collaboration. In this special edition of the Mok Talk interview series, hosted by the talented Professor Yang Xia of The Second Affiliated Hospital of Zhejiang University School…
-
EAU 2025 | Professors Haige Chen and Ruiyun Zhang Share Advances in Non-Invasive Bladder-Sparing Detection and Targeted-Immunotherapy Combinations
Trimodality therapy (TMT)is a well-established bladder-sparing strategy for patients with muscle-invasive bladder cancer (MIBC). However, limitations remain for patients intolerant to chemotherapy and in monitoring post-treatment recurrence. Professors Haige Chen and Ruiyun Zhang of Renji Hospital, Shanghai Jiao Tong University School of Medicine, have long focused on MIBC research. This year, nine of their studies…
-
SGBCC 2025 | Prof. Zefei Jiang has an in-depth dialogue with Prof. Michael Gnant: Combining Chinese and Western Approaches and Listening to the Voice of China at SGBCC
From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC) was held with great success. During the conference, the Chinese Society of Clinical Oncology (CSCO) and SGBCC jointly organized the “Voice of China” session, showcasing China’s advancements in clinical research, basic science, translational medicine, and radiomics within the breast cancer field,…
-
Real-World Evidence Supports Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases
In a multicenter observational study across 12 Italian oncology units, Dr. Alessandra Fabi and colleagues evaluated the real-life effectiveness of Trastuzumab Deruxtecan (T-DXd) in 39 patients with HER2-positive breast cancer…
-
Epigenetics in Breast Cancer: The Rise of Precision Medicine
Published in Breast Cancer (Springer) in June 2024,Sujata Purja, Dung Thuy Nguyen, and Eunyong Kim provide a comprehensive analysis of the evolving landscape of breast cancer epigenetics, emphasizing the therapeutic…
Connecting Medical Expertise through Media